Emergent BioSolutions (NYSE:EBS) Rating Reiterated by Benchmark

Benchmark restated their buy rating on shares of Emergent BioSolutions (NYSE:EBS) in a research note released on Tuesday, Benzinga reports. The brokerage currently has a $8.00 price target on the biopharmaceutical company’s stock.

Emergent BioSolutions Price Performance

EBS stock opened at $7.94 on Tuesday. Emergent BioSolutions has a 1 year low of $1.42 and a 1 year high of $8.29. The firm has a 50-day moving average of $5.54 and a 200 day moving average of $3.38. The company has a market cap of $415.79 million, a P/E ratio of -0.72 and a beta of 1.62. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.08 and a quick ratio of 0.55.

Emergent BioSolutions (NYSE:EBS) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of ($3.65) by $4.24. Emergent BioSolutions had a negative net margin of 47.68% and a negative return on equity of 18.53%. The business had revenue of $300.40 million during the quarter. During the same period in the prior year, the business posted ($3.17) EPS. On average, sell-side analysts forecast that Emergent BioSolutions will post -1.98 EPS for the current year.

Insider Buying and Selling at Emergent BioSolutions

In other Emergent BioSolutions news, Director Kathryn C. Zoon sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $6.11, for a total transaction of $61,100.00. Following the completion of the transaction, the director now owns 54,482 shares of the company’s stock, valued at $332,885.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders sold 12,919 shares of company stock valued at $75,831. Corporate insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Emergent BioSolutions

Institutional investors have recently made changes to their positions in the company. CoreCap Advisors LLC purchased a new stake in shares of Emergent BioSolutions during the fourth quarter valued at approximately $33,000. Avidian Wealth Solutions LLC purchased a new stake in shares of Emergent BioSolutions during the first quarter valued at approximately $33,000. Tidal Investments LLC purchased a new stake in Emergent BioSolutions in the first quarter worth approximately $34,000. Laurion Capital Management LP purchased a new stake in Emergent BioSolutions in the third quarter worth approximately $37,000. Finally, Tower Research Capital LLC TRC boosted its holdings in Emergent BioSolutions by 52.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 19,867 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 6,823 shares during the last quarter. Hedge funds and other institutional investors own 78.40% of the company’s stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.